Brief: Alkermes Announces Settlement With Teva Related To Vivitrol Patent Litigation

Alkermes

30/08/2023 12:03

Aug 30 (Reuters) - Alkermes Plc  ALKS.O :
    * ALKERMES ANNOUNCES SETTLEMENT WITH TEVA RELATED TO
VIVITROL®
PATENT LITIGATION
    * ALKERMES PLC- COMPANY GRANTS TEVA A LICENSE TO MARKET
GENERIC
VIVITROL BEGINNING IN JANUARY 2027
    * ALKERMES PLC - ADDITIONAL DETAILS REGARDING SETTLEMENT
AGREEMENT
WERE NOT DISCLOSED
    * ALKERMES PLC - CO,TEVA WILL SUBMIT SETTLEMENT AGREEMENT
FOR
REVIEW TO UNITED STATES FEDERAL TRADE COMMISSION AND UNITED
STATES DEPARTMENT OF JUSTICE
    * ALKERMES: CO AND TEVA WILL SUBMIT SETTLEMENT AGREEMENT FOR
REVIEW TO UNITED STATES FEDERAL TRADE COMMISSION AND UNITED
STATES DEPARTMENT OF JUSTICE
    * ALKERMES: CO, TEVA WILL FILE A PROPOSED STIPULATED CONSENT
JUDGMENT AND INJUNCTION WITH U.S. DISTRICT COURT FOR DISTRICT OF
NEW JERSEY
    * ALKERMES PLC- CO, TEVA WILL FILE PROPOSED STIPULATED
CONSENT
JUDGMENT AND INJUNCTION REQUESTING THAT COURT DISMISS PENDING
LITIGATION BETWEEN PARTIES
    * ALKERMES PLC: PROPOSED STIPULATED CONSENT JUDGMENT AND
INJUNCTION REQUESTS COURT DISMISS PENDING LITIGATION BETWEEN CO,
TEVA

Source text for Eikon:  ID:nPn2LXPG2a 
Further company coverage:  ALKS.O